A Valujskikh1, A M VanBuskirk, C G Orosz, P S Heeger. 1. Department of Medicine, Case Western Reserve University and The Louis Stokes Cleveland Department of Veterans Affairs Medical Center, Ohio 44106, USA.
Abstract
BACKGROUND: Intravenous injection of soluble antigen has been reported to induce immunologic tolerance through a variety of mechanisms including T-cell deletion, anergy, and suppression. To clarify the reported discrepancies, we studied mechanisms of intravenous tolerance to a defined transgenic minor transplantation antigen in mice. METHODS: Wild-type C57BL/6 (B6) mice or congenic B6 B-cell knockout mice were made tolerant to beta-galactosidase (beta-gal). Clinical tolerance was assessed by placement of B6 beta-gal transgenic (tg) and third-party skin grafts. In vitro analysis of T- and B-cell immunity and in vivo treatment with anti-TGFbeta antibodies were used to define mechanisms of induced tolerance. RESULTS: Intravenous injection of beta-gal induced true immunologic tolerance to beta-gal tg skin in wild-type but not in B-cell-deficient recipients, suggesting that antigen presentation by B cells was required for the effect. The tolerogenic manipulation primed a population of CD4+, beta-gal-specific, TGFbeta-producing T cells. Although evidence for both anergy and suppression were observed, subsequent data demonstrated that TGFbeta was a critical immunoregulatory mediator of the tolerant state: neutralizing anti-TGFbeta antibodies fully prevented the induction of tolerance to B6 beta-gal tg skin grafts. Second male beta-gal tg grafts placed onto female recipients that were previously made tolerant to female beta-gal tg skin were rapidly rejected, however, suggesting that this TGFbeta-induced tolerance could not be linked to additional antigenic determinants. CONCLUSIONS: The studies demonstrate a critical role for TGFbeta in mediating tolerance after intravenous injection of antigen but additionally raise concerns about the stability of this tolerant state.
BACKGROUND: Intravenous injection of soluble antigen has been reported to induce immunologic tolerance through a variety of mechanisms including T-cell deletion, anergy, and suppression. To clarify the reported discrepancies, we studied mechanisms of intravenous tolerance to a defined transgenic minor transplantation antigen in mice. METHODS: Wild-type C57BL/6 (B6) mice or congenic B6 B-cell knockout mice were made tolerant to beta-galactosidase (beta-gal). Clinical tolerance was assessed by placement of B6 beta-gal transgenic (tg) and third-party skin grafts. In vitro analysis of T- and B-cell immunity and in vivo treatment with anti-TGFbeta antibodies were used to define mechanisms of induced tolerance. RESULTS: Intravenous injection of beta-gal induced true immunologic tolerance to beta-gal tg skin in wild-type but not in B-cell-deficient recipients, suggesting that antigen presentation by B cells was required for the effect. The tolerogenic manipulation primed a population of CD4+, beta-gal-specific, TGFbeta-producing T cells. Although evidence for both anergy and suppression were observed, subsequent data demonstrated that TGFbeta was a critical immunoregulatory mediator of the tolerant state: neutralizing anti-TGFbeta antibodies fully prevented the induction of tolerance to B6 beta-gal tg skin grafts. Second male beta-gal tg grafts placed onto female recipients that were previously made tolerant to female beta-gal tg skin were rapidly rejected, however, suggesting that this TGFbeta-induced tolerance could not be linked to additional antigenic determinants. CONCLUSIONS: The studies demonstrate a critical role for TGFbeta in mediating tolerance after intravenous injection of antigen but additionally raise concerns about the stability of this tolerant state.
Authors: Antonio J Buendía; Laura Del Río; Nieves Ortega; Joaquín Sánchez; María C Gallego; María R Caro; Jose A Navarro; Francisco Cuello; Jesús Salinas Journal: Infect Immun Date: 2002-12 Impact factor: 3.441
Authors: Kenneth A Newell; Adam Asare; Allan D Kirk; Trang D Gisler; Kasia Bourcier; Manikkam Suthanthiran; William J Burlingham; William H Marks; Ignacio Sanz; Robert I Lechler; Maria P Hernandez-Fuentes; Laurence A Turka; Vicki L Seyfert-Margolis Journal: J Clin Invest Date: 2010-05-24 Impact factor: 14.808
Authors: Richard Verbeek; Koen van der Mark; Eric F Wawrousek; Arianne C Plomp; Johannes M van Noort Journal: Immunology Date: 2007-04-26 Impact factor: 7.397
Authors: Xiaolun Huang; Daniel J Moore; Robert J Ketchum; Craig S Nunemaker; Boris Kovatchev; Anthony L McCall; Kenneth L Brayman Journal: Endocr Rev Date: 2008-07-29 Impact factor: 19.871
Authors: Cavit D Kant; Yoshinobu Akiyama; Katsunori Tanaka; Susan Shea; Sarah E Connolly; Sharon Germana; Henry J Winn; Christian LeGuern; Georges Tocco; Gilles Benichou Journal: J Immunol Date: 2013-07-05 Impact factor: 5.422
Authors: Cavit D Kant; Yoshinobu Akiyama; Katsunori Tanaka; Susan Shea; Yohei Yamada; Sarah E Connolly; Jose Marino; Georges Tocco; Gilles Benichou Journal: J Immunol Date: 2014-12-22 Impact factor: 5.422